ALPN · Alpine Immune Sciences
Acquired Company
Vertex Pharmaceuticals completed the acquisition of Alpine Immune Sciences for $65 per share in cash, for a total value of approximately $4.9 billion, with Alpine delisted from Nasdaq on May 19, 2024.
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune / inflammatory disorders, and other diseases. The company is headquartered in Seattle, Washington.
188 EAST BLAINE STREET, SEATTLE, WA, UNITED STATES, 98102, Washington, 98102, USA
BIOTECHNOLOGY
HEALTHCARE
Market Cap
4.457B
52 Wk Range
$0.00 - $0.00
Previous Close
$64.97
Open
$64.97
Volume
N/A
Day Range
$64.97 - $64.97
Enterprise Value
N/A
Cash
33.02M
Avg Qtr Burn
-27.69M
Insider Ownership
4.65%
Institutional Own.
99.47%
Qtr Updated
Mar 31st 2024